Could a common antioxidant shield cancer patients from painful mouth sores?

NCT ID NCT07736495

First seen Jul 30, 2026 · Last updated Jul 31, 2026 · Updated 1 time

Summary

This trial tests whether alpha-lipoic acid, a powerful antioxidant, can prevent oral mucositis—painful mouth sores—caused by the chemotherapy drug 5-fluorouracil in colorectal cancer patients. Half of the 50 participants will take alpha-lipoic acid twice daily for six months, while the other half receive a placebo. The study measures oxidative stress levels and tracks how many patients develop mouth sores, aiming to see if this simple supplement can ease a common and distressing side effect.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
alpha-lipoic acid 600 mg twice daily
What this could lead to
If it works, this could offer a simple, low-cost way to prevent a painful side effect of chemotherapy, improving quality of life and treatment adherence.
What could go wrong
This is a small, early-phase trial. The antioxidant effect may not translate into fewer mouth sores, and alpha-lipoic acid could interact with chemotherapy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Nasser Institute for Research and Treatment.

    RECRUITING

    Cairo, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.